About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2019

Annual Report 2018

  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery


  Biocon Academy


  Facilities Virtual Tour

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon was among the early movers in industry to pursue a high risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, Middle East & Turkey, Asia-Pacfic regions and also now in developed markets of U.S., EU and Japan.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceuticals player.



Biocon Performance Highlights of Q1FY20 by Kiran Mazumdar-Shaw, CMD, Biocon Ltd.

Biocon Corporate Overview
Stock Update


Company Announcements


Nov 12, 2019 
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year

Nov 05, 2019 
Biocon's Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA

Oct 28, 2019 
Biocon Moves Up to Rank No. 6 on Science Career' Top 20 Global Pharma & Biotech Employers List 2019

  Media Coverage  

Oct 30, 2019:
Indian company makes it to top 10 best employers in biotech category

Oct 29, 2019
Biocon moves up to 6th spot in top 10 Global Biotech Employers ranking

Oct 26, 2019:
Insulin at ₹7 will be a gamechanger for us

Oct 25, 2019:
Biocon sets $1 billion target for biologics business



Biocon Malaysia







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved